B
Beijing Saite Mingqiang Pharmaceutical Technology
AI-driven small molecule drug discovery and development
About Beijing Saite Mingqiang Pharmaceutical Technology
Beijing Saite Mingqiang Pharmaceutical Technology, also known as Scitech Pharma, is a company focused on the research and development of innovative small molecule drugs. Founded in 2015 and headquartered in Beijing, the company concentrates on therapeutic areas such as oncology, autoimmune diseases, and central nervous system disorders. The legal representative for the company is Wang Kexiu.
The company's business model is centered around its proprietary AI-driven drug design and screening platform, SigmaHIT®. This technology facilitates the discovery and optimization of small molecule drug candidates, moving them from conception through preclinical studies and into clinical evaluation. Scitech Pharma has established a significant research and development infrastructure, including a 20,000-square-meter base with 11 specialized laboratories for chemistry, biology, animal studies, and more. Their drug pipeline includes several in-house projects, with some candidates advancing to Phase I and Phase II clinical trials in China. The company has secured over 100 patents, with the majority being international.
Scitech Pharma operates as a privately held, venture capital-backed entity. It has successfully completed multiple funding rounds, including a Series A round in August 2022 and a later-stage venture round in April 2024, attracting investors like Zhizhong Investment, Elikon Venture, and Hangzhou Tigermed Consulting Company.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 13.7/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2024 | $14M | $55M | Lichen Investment · Zhizhong Investment · Hangzhou Tigermed | ↗ |
Growth signals
Latest recorded traffic for Beijing Saite Mingqiang Pharmaceutical Technology is 710 monthly website visits, up 407.1% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Saite Mingqiang Pharmaceutical Technology in its local ecosystem
The Beijing Saite Mingqiang Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- LILichen Investment
- ZIZhizhong Investment
Hangzhou Tigermed
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Saite Mingqiang Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Saite Mingqiang Pharmaceutical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.